Coverage file · who pays what now
The $50 question: Medicare’s GLP-1 Bridge, TrumpRx, and the 2026 channel maze — decoded by insurance status
The November 2025 pricing deals between the government and both major manufacturers rebuilt the entire payment landscape in under a year — and left behind the most confusing channel maze this category has ever had. The map, compressed: Medicare Part D members got the headline — the GLP-1 Bridge pilot (July 1, 2026 – December 31, 2027) puts Wegovy (injection and tablet), the Zepbound KwikPen, and Foundayo at a $50/month copay for members meeting BMI-tier criteria, running outside the normal Part D benefit with real fine print. Medicaid is a state patchwork — roughly a dozen-plus states cover obesity GLP-1s, several dropped out January 1, and most enrollees still have no pathway. The cash-pay uninsured got TrumpRx, a government portal of coupons and manufacturer links with launch-era prices like ~$149 for the Wegovy tablet’s lowest dose and ~$299+ for Zepbound — snapshots that shift by month on a published glidepath toward ~$245 over two years. The commercially insured still live and die by formulary status and ~$25 savings cards. And underneath all of it, the audited compounded floor — $119–$169/month flat, dose-proof, month-to-month — remains the benchmark every channel gets measured against, especially at the maintenance doses where brand ladders climb to $449 and beyond. Your lane, your fine print, and your action list — by insurance status — below. (Compounded formulations use the same active ingredient as brand products; not FDA-approved as finished drugs.)
The November deals — one paragraph of context
In November 2025 the administration announced agreements with both major GLP-1 manufacturers trading pricing concessions for access expansion: a ~$245 reference price for currently marketed injectables in government programs, $50 beneficiary copay caps in the Medicare pilot lane, cash-pay channel prices starting around $350 and stepping toward ~$245 over two years, and oral GLP-1 starter doses slated near $149–$150 — all operationalized through 2026 as the TrumpRx portal (January), the Wegovy tablet launch (pharmacies from January), Foundayo’s approval (April), and the Medicare Bridge going live July 1. Everything below is those commitments meeting reality — with dates attached, because in this landscape an undated price is already a wrong one.
The Medicare Bridge, decoded — the $50 lane and its fine print
The mechanics as reported: from July 1, 2026 through December 31, 2027, eligible Part D members can get Wegovy (injection or tablets), the Zepbound KwikPen, or Foundayo for a $50 monthly copay when prescribed for weight management. Eligibility runs on BMI tiers — reported as roughly BMI ≥35 alone, ≥30 with a qualifying heart or kidney condition, or ≥27 with prediabetes or established cardiovascular disease — with estimates of the qualifying population running as high as ~14 million members. The fine print that headlines skipped: the Bridge operates outside the standard Part D benefit — the $50 payments don’t count toward your deductible or the $2,100 out-of-pocket cap, plans don’t have to opt in, and the longer-term BALANCE demonstration that was supposed to follow was postponed indefinitely in Part D this April (it launched in Medicaid in May), with Bridge data feeding the later decision. Translation for planning: this is a real, funded, time-limited lane — an eighteen-month window, not a permanent benefit — and the section on compounded structure below explains why that expiry date belongs in your budget math, not just your news feed. Documentation-wise, everything this site teaches about coverage paperwork applies: diagnosis coding, BMI documentation, and treatment-response records make eligibility conversations short.
The Medicaid patchwork — the map most coverage stories skip
Medicaid coverage for obesity GLP-1s is decided state by state, and 2026’s honest snapshot is sobering: roughly thirteen state fee-for-service programs cover them — down from sixteen after several states ended coverage January 1 — leaving around 80% of adult enrollees with no obesity-GLP-1 pathway, even as the BALANCE demonstration began enrolling on the Medicaid side in May. If you’re on Medicaid: your state’s current status is a five-minute pharmacy-benefit lookup, the diabetes-indication lane (where clinically real) remains separate from the obesity lane, and state decisions have proven reversible in both directions — which makes the annual re-check habit a Medicaid survival skill, not a luxury.
TrumpRx, decoded — what the portal is and isn’t
TrumpRx (live since January) is not a pharmacy — it’s a government-run discount portal: coupons usable at retail pharmacies plus links to manufacturers’ direct channels, for people buying without insurance. Published snapshots have moved with the calendar, which is itself the lesson: early-year reporting showed the Wegovy tablet’s lowest dose near $149, Wegovy and Ozempic pens near $199, and Zepbound near $299; spring reporting showed Wegovy injectables spanning $199–$399 by dose, the Wegovy tablet up to $299, Foundayo topping near $349, and the Zepbound KwikPen reaching as high as $699 in that channel — all against the deals’ published glidepath of cash prices stepping from ~$350 toward ~$245 over two years. Working rules: treat every TrumpRx figure as dose-specific and dated, compare the portal’s coupon route against the manufacturer’s own direct program before assuming which is cheaper (they diverge — next section), and remember the portal’s existence changes nothing about the first commandment: a covered ~$25–$50 lane beats every cash lane, so eligibility checks come first.
The self-pay channel maze — the traps worth naming
Buying brand for cash in 2026 means navigating ladders with teeth. The LillyDirect vial ladder (as reported in June): Zepbound single-dose vials at $299 (2.5 mg), $399 (5 mg), and $449 for every dose from 7.5–15 mg — with the trap in the footnote: those higher-dose prices hold only when you refill within 45 days of the prior delivery; miss the window and the 12.5/15 mg vials reportedly reprice to $849–$1,049. A single skipped month — a vacation, a tolerance break, a shipping snag — can double the bill, which is dose-tier pricing’s failure mode wearing its sharpest suit; the vial decoder covers the ladder rung by rung. The NovoCare side: starter-dose promos (reported $199 first fills, stepping to ~$349 after the promotional window) follow launch-pricing physics — the door price and the living price differ. The universal rule this maze teaches: price the dose you’ll maintain on, price the miss-a-month scenario, and read the refill-window and auto-ship terms with the ten-minute method before any card gets stored.
Where compounded fits now — the benchmark that keeps everyone honest
The brand price war narrowed the gap — and at maintenance doses, the gap is still the story. The audited compounded floor holds at $119–$139/month semaglutide and $139–$169/month tirzepatide — flat, dose-proof, month-to-month, thirty-day written cancellation — against brand self-pay ladders that live at $299–$449+ at maintaining doses with refill-window traps attached: the audited flat benchmark, dated ↗ (compounded; same active ingredient as brand; not FDA-approved as finished drugs). Structure matters as much as sticker here: the Bridge expires December 2027, TrumpRx snapshots move monthly, promos sunset — and a month-to-month flat plan is the position that lets you exploit every one of those lanes the moment one opens for you, with nothing prepaid to strand and no ladder to fall off. That’s the same structural-readiness logic the regulatory file teaches, pointed at pricing weather instead of dockets. And the eligibility ordering never changes: covered $25–$50 lanes first, then the cash math — this site’s boards exist to make the second step take five minutes.
The action list — by insurance status, this week
Medicare Part D: check your BMI-tier fit against the Bridge criteria, confirm your plan’s participation posture, get the qualifying documentation into your chart, and calendar the December 2027 sunset with a plan-B note. Medicaid: look up your state’s current obesity-coverage status (and re-check each January — states move). Commercially insured: formulary check, prior-auth requirements, then the ~$25 card — the appeal anatomy if denied, because denials in 2026 reverse more than people think. Uninsured or excluded: price your maintenance dose across TrumpRx, the manufacturers’ direct programs (mind the 45-day windows), and the audited compounded floor — then choose on structure, not sticker. Everyone: date-stamp whatever number you decide on, because in this market a price without a date is a rumor — and set the annual review, because every lane above will look different by then.
FAQ
What is the Medicare GLP-1 Bridge program?
A pilot running July 1, 2026 – December 31, 2027 giving eligible Part D members Wegovy (injection/tablets), the Zepbound KwikPen, or Foundayo at a $50/month copay under BMI-tier criteria — outside the normal Part D benefit, so the $50 doesn’t count toward deductibles or the out-of-pocket cap.
Who qualifies for the $50 Medicare GLP-1 copay?
Reported tiers: BMI ≥35 alone; ≥30 with a qualifying heart or kidney condition; or ≥27 with prediabetes or established cardiovascular disease — with plan participation and documentation requirements on top; estimates put the eligible population as high as ~14 million.
What does TrumpRx charge for GLP-1s?
Snapshot prices by dose and date — launch-era figures included ~$149 for the lowest-dose Wegovy tablet and ~$299 for Zepbound, with spring ranges of $199–$399 for Wegovy injectables — on a published glidepath toward ~$245 over two years. Always compare against manufacturers’ direct programs and any covered lane first.
Is compounded still cheaper than the new brand prices?
At maintenance doses, generally yes — the audited flat floor runs $119–$169/month dose-proof versus $299–$449+ brand self-pay ladders with refill-window traps; covered $25–$50 lanes beat both, which is why eligibility checks always come first.